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Abstract
Chemotherapeutic agents are rarely used for symptom management in patients under palliative
care setting. This is because chemotherapeutic agents not only have limited efficacy in palliative
treatment but are also known to exert severe adverse effects. We describe our experience with a
patient with metastatic breast cancer who was successfully treated with low-dose capecitabine,
without the development of any severe toxicities and with significant improvement in activities of
daily living (ADL) and quality of life (QOL).
The patient, a 43-year-old female, had breast cancer with liver, bone, and cutaneous metastases.
She visited our clinic after a year-long hiatus during which she underwent alternative therapy. She
presented with ulcerated lesions on the anterior chest and dyspnea due to malignant pleural
effusion. After treatment for the latter, we administered capecitabine (600 mg/day) in accordance
with the wishes of the patient and her attendants. The ulcerated lesions on the anterior chest,
dyspnea, ADL and QOL improved significantly, without the development of any serious adverse
effects. The findings of this case indicate that chemotherapy in the form of low-dose capecitabine
monotherapy may be considered in patients under palliative care setting.
Background
In palliative care, chemotherapy is as useful as watchful
waiting. However, when prescribing chemotherapy for
palliative treatment, an important consideration is
whether chemotherapeutic agents should be administered
on a daily basis. Koedoot et al reported that the patient's
age and wishes and the expected survival gain from treat-
ment are factors that influence the decision of therapy.[1]
Thus, this decision represents a choice between practice
and ethics, in other words, between efficacy and adverse
effects.
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Generally, because poor performance status (PS) is associ-
ated with poor prognosis,[2] oncologists are reluctant to
administer chemotherapy to patients with poor PS. We
describe a case of metastatic breast cancer where the East-
ern Cooperative Oncology Group (ECOG) PS score was 4.
The patient was treated with low-dose capecitabine, in
accordance with her wishes. Despite being administered
in a low dose, this chemotherapeutic agent effected a sig-
nificant improvement in the patient's activities of daily
living (ADL) and quality of life (QOL) without any severe
toxicities.
Case presentation
Patient characteristics and chief complaints
The patient was a 43-year-old Asian female with meta-
static breast cancer who visited our clinic after a year-long
period of treatment suspension for undergoing alternative
therapy. The patient presented with ulcerated lesions on
the anterior chest and dyspnea due to malignant pleural
effusion. Apart from the reported complaints, the
patient's medical history was unremarkable; and so were
the family and social histories.
History of present illness
The patient was diagnosed with invasive ductal carcinoma
of the left breast (Stage IIIb) on February 2004. Patholog-
ical examination of the needle biopsy sample was per-
formed. Immunohistochemical analysis revealed that the
tumor cells were positive for estrogen receptors and pro-
gesterone receptors and overexpression of human epider-
mal growth factor receptor 2 (HER2) overexpression. The
tumor was graded as intermediate (grade 2) according to
the nuclear grading system. The patient was administered
doxorubicin and cyclophosphamide, followed by
docetaxel as neoadjuvant chemotherapy. Trastuzumab
was later added to the chemotherapy regimen. However,
there was recurrence of the breast cancer, for which she
was treated with weekly doses of paclitaxel and trastuzu-
mab. On April 2005, after trans-areolar total glandec-
tomy, she was readministered trastuzumab. However,
local and axillary recurrence of the tumor occurred 4 and
2 times, respectively. The tumor cells tested negative for
estrogen receptors and progesterone receptors; however,
HER2 overexpression persisted. She received a combina-
tion therapy of vinorelbine and trastuzumab. Thereafter,
treatment from our clinic was stopped for a year since the
patient wanted to undergo alternative therapy. She revis-
ited our clinic in January 2009 for ulcerated lesions on the
anterior chest and severe dyspnea. Positron-emission
tomography (PET) revealed bilateral increased uptake of
18F-fluorodeoxyglucose in the metastatic lesions of the
chest wall, liver, and multiple bone metastases.
Course
At presentation, the patient was cachexic, had edema sec-
ondary to malnutrition, and had moderate dyspnea due
to malignant pleural effusion. We admitted her to a
municipal hospital for 1 week her general condition
improved. Intercostal tube drainage for malignant pleural
effusion improved the patient's dyspnea. We believed that
the patient could survive for 3 months after this treat-
ment. However, she and her family were of the opinion
that she be administered chemotherapy and managed at
home. Therefore, we prescribed low-dose capecitabine
(600 mg/day). The cycle of treatment was 3 consecutive
weeks of drug administration followed by a 1-week rest
period. Significant improvements after the first cycle were
seen in the ulcerated lesions of the anterior chest and dys-
pnea, without the development of any severe adverse
effects. After 2 cycles, the cutaneous lesions had resolved
almost completely (Figure 1) and there was improvement
of ADL and QOL. After 3 cycles, PET and computed tom-
ography (CT) were performed. Tumor shrinkage was seen
in the breast and liver (Figure 2, Figure 3). Although there
was recurrence of pleural effusion, the patient did not
experience much discomfort and did not have symptoms
such as shortness of breath. Finally, the patient discontin-
ued capecitabine at her own discretion because of slight
hair loss.
Discussion
In palliative oncology, the relevance of chemotherapy as a
palliative treatment has not been established clearly.
Some studies have reported that chemotherapy as pallia-
tive treatment is effective in improving the patient's QOL
score,[3,4] but other studies on this topic report that there
was no change in this score.[5]
Capecitabine, an orally administered fluoropyrimidine
carbamate, has been proven to be effective for metastatic
breast cancer. In particular, oral capecitabine mono-
therapy has been shown to improve the QOL in patients
who were previously treated for metastatic breast can-
cer.[6]
Our patient was treated with low-dose (600 mg/day)
capecitabine monotherapy. Silva et al.[7] reported the
effectiveness of low-dose capecitabine (1500 mg·/m-2·/
day) with low-dose docetaxel; however, there are no
reports on the use of low-dose capecitabine monotherapy.
In preliminary and phase I studies on capecitabine, no
grade 3 to 4 toxicities were seen at a dose of 502 mg/·m-
2·/day.[8,9] In line with this result, no severe adverse
effects were observed in our patient at a dose level of
approximately 500 mg/m-2·/day. In the drug packages
marketed in Japan, the package insert indicates that the
standard dose of this drug is 1800 mg/day. Generally,
tumor response to capecitabine treatment is not expectedCases Journal 2009, 2:9081 http://www.casesjournal.com/content/2/1/9081
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at low doses (e.g. 600 mg/day) of the drug. The key deter-
minants of fluorouracil sensitivity are the enzymes thymi-
dilate synthase, thymidine phosphorylase and
dihydropyrimidine dehydrogenase.[10]Favorable
changes in the activity levels of these enzymes and some
genetic factors may positively influence tumor response to
the drug, and palliation may be achieved without the
development of severe toxicities.
In a retrospective study of patients with cutaneous metas-
tases, Lookingbill et al. reported that breast cancer is the
commonest primary tumor in females.[11] There is no
specific systemic chemotherapy for cutaneous metastases
of breast cancer, but Sideras et al. reported that capecitab-
ine therapy elicited significant response with resolution of
cutaneous metastases.[12] Because wound odor and exu-
dates result in a deterioration of the QOL, we think that
chemotherapy with low-dose capecitabine as palliative
treatment may provide clinically meaningful outcomes.
a) Cutaneous metastases with ulcerated lesions of breast cancer on the anterior chest wall Figure 1
a) Cutaneous metastases with ulcerated lesions of breast cancer on the anterior chest wall. b) Shrinking metas-
tases and reduction of ulcerated lesions after chemotherapy.
a) Positron emission tomography scan shows bilateral large masses in the chest wall Figure 2
a) Positron emission tomography scan shows bilateral large masses in the chest wall. b) Decrease in tumor mass 
after chemotherapy.Cases Journal 2009, 2:9081 http://www.casesjournal.com/content/2/1/9081
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Conclusion
This case showed low-dose capecitabine dramatically
improved the patient's ADL and QOL. In fact, the PS score
of this patient improved from 4 to 1. In palliative oncol-
ogy, it is suggested that chemotherapy in the form of low-
dose capecitabine monotherapy can be considered as a
viable option for palliative management of metastatic
breast cancer.
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